trending Market Intelligence /marketintelligence/en/news-insights/trending/tvm3ynqq-16jduulauwjka2 content esgSubNav
In This List

NYSE accepts CorMedix's plan to regain compliance with listing requirements

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


NYSE accepts CorMedix's plan to regain compliance with listing requirements

CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.

The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.

The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.

CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.